Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ACOR - Acorda Therapeutics rises postmarket after quarterly loss narrows 75%

ACOR - Acorda Therapeutics rises postmarket after quarterly loss narrows 75%

Acorda Therapeutics Inc.
Acorda Therapeutics (NASDAQ:ACOR) is up 2% in after-hours trading following the biotech's Q4 2021 and full-year earnings. The company's net loss narrowed 75% in the quarter to $20.6M (-$1.73 per share, basic and diluted) compared to the prior-year period. Revenue of ~$37M was a ~3% year-over-year decline. Acorda (ACOR) was helped in the quarter by a 58% decline in operating expenses compared to Q4 2020 to $48.5M. Acorda (ACOR) is projecting 2022 revenue of Ampyra (dalfampridine) of $68M-$78M. The company ended the year with $45.6M in cash. Read why Seeking Alpha contributor Bret Jensen considers Acorda (ACOR) a hold.

For further details see:

Acorda Therapeutics rises postmarket after quarterly loss narrows 75%
Stock Information
Company Name: Acorda Therapeutics Inc.
Stock Symbol: ACOR
Market: NASDAQ
Website: acorda.com
Menu
ACOR ACOR Quote ACOR Short ACOR News ACOR Articles ACOR Message Board
Get ACOR Alerts

News, Short Squeeze, Breakout and More Instantly...